Canan Alhan

Amsterdam, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

Lenalidomide boosts CD1d-Vδ2 bispecific antibody-engaged Vγ9Vδ2-T cell effector functions via CD28, Notch signaling and IL-2 release.

Lenalidomide boosts CD1d-Vδ2 bispecific antibody-engaged Vγ9Vδ2-T cell effector functions via CD28, Notch signaling and IL-2 release.

Journal: Journal for immunotherapy of cancer

Published: June 11, 2026

Prognostic value of measurable residual disease in high-risk MDS after intensive chemotherapy in HOVON-SAKK studies.

Prognostic value of measurable residual disease in high-risk MDS after intensive chemotherapy in HOVON-SAKK studies.

Journal: HemaSphere

Published: February 26, 2026

Pharmacological boosting of azacitidine/venetoclax in acute myeloid leukemia.

Pharmacological boosting of azacitidine/venetoclax in acute myeloid leukemia.

Journal: Blood neoplasia

Published: December 02, 2025

Development of Machine-Assisted, Human-Centred Bone Marrow Cell Classification: Feasibility Analysis in Patients With Myelodysplastic Syndromes.

Development of Machine-Assisted, Human-Centred Bone Marrow Cell Classification: Feasibility Analysis in Patients With Myelodysplastic Syndromes.

Journal: EJHaem

Published: March 14, 2025

Validation of the diagnostic potential of 17 immunophenotypic core markers defined by the ELN-iMDS-Flow Working Group in an independent cohort of patients with MDS.

Validation of the diagnostic potential of 17 immunophenotypic core markers defined by the ELN-iMDS-Flow Working Group in an independent cohort of patients with MDS.

Journal: HemaSphere

Published: October 14, 2024

Expression levels of genes implicated in the working mechanism of lenalidomide predict treatment response in lower risk myelodysplastic syndrome patients.

Expression levels of genes implicated in the working mechanism of lenalidomide predict treatment response in lower risk myelodysplastic syndrome patients.

Journal: Haematologica

Published: August 05, 2024

Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial.

Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial.

Journal: Leukemia

Published: June 30, 2023

Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues: Recommendations from the European LeukemiaNet/International Myelodysplastic Syndrome Flow Cytometry Working Group.

Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues: Recommendations from the European LeukemiaNet/International Myelodysplastic Syndrome Flow Cytometry Working Group.

Journal: Cytometry. Part B, Clinical cytometry

Published: September 29, 2021

Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS-Flow Cytometry Working Group.

Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS-Flow Cytometry Working Group.

Journal: Cytometry. Part B, Clinical cytometry

Published: July 09, 2021

Flow cytometric analysis of myelodysplasia: Pre-analytical and technical issues-Recommendations from the European LeukemiaNet.

Flow cytometric analysis of myelodysplasia: Pre-analytical and technical issues-Recommendations from the European LeukemiaNet.

Journal: Cytometry. Part B, Clinical cytometry

Published: July 01, 2021

Dysplasia and PNH-type cells in bone marrow aspirates of myelodysplastic syndromes.

Dysplasia and PNH-type cells in bone marrow aspirates of myelodysplastic syndromes.

Journal: Cytometry. Part B, Clinical cytometry

Published: July 01, 2021

Distinct bone marrow immunophenotypic features define the splicing factor 3B subunit 1 (SF3B1)-mutant myelodysplastic syndromes subtype.

Distinct bone marrow immunophenotypic features define the splicing factor 3B subunit 1 (SF3B1)-mutant myelodysplastic syndromes subtype.

Journal: British journal of haematology

Published: December 14, 2020

Showing 1-12 of 31

Last Updated: 09/26/2026